Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. Th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 798 6700

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

2pumps1dump Aug. 18 at 7:28 PM

$ERNA

0 · Reply

JimmyOcarri Aug. 17 at 7:43 PM

$ARBB $STFS $XXII $ERNA $SLMT gemss

0 · Reply

Gdori Aug. 15 at 6:23 AM

$ERNA When will they announce the results?

0 · Reply

2pumps1dump Aug. 12 at 5:39 AM

$ERNA IND Submission

0 · Reply

Equilibrium_For_All Aug. 11 at 7:26 PM

$ERNA will someone just buy here.... Volume so low. Any small buys sends this up, imagine a bigger buy, it would fly!

0 · Reply

2pumps1dump Aug. 11 at 6:05 AM

$ERNA primed, oversold.

0 · Reply

Ernexatx Aug. 10 at 2:06 PM

$ERNA Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage https://www.globenewswire.com/news-release/2026/08/10/3341879/0/en/ernexa-therapeutics-strengthens-board-with-veteran-biotech-executive-david-polinsky-as-company-approaches-clinical-stage.html

0 · Reply

SuminskiStonks Aug. 7 at 1:35 PM

$ERNA Some good news and let’s take this back to 12-15

0 · Reply

KiserSose Aug. 7 at 2:40 AM

$ERNA Float is less than 700k

0 · Reply

KiserSose Aug. 7 at 2:35 AM

$ERNA all this stock needs is good news..10 bucks here we come

0 · Reply

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Jul 24, 2026, 9:20 AM EDT - 25 days ago

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

2026-07-15T12:15:21.000Z - 5 weeks ago

Ernexa Therapeutics announces new ERNA-101 preclinical data

Jul 15, 2026, 7:50 AM EDT - 5 weeks ago

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

Jul 14, 2026, 9:01 AM EDT - 5 weeks ago

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

Jun 25, 2026, 9:15 AM EDT - 7 weeks ago

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

Jun 17, 2026, 8:47 AM EDT - 2 months ago

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Jun 9, 2026, 8:41 AM EDT - 2 months ago

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

2026-05-27T14:06:25.000Z - 2 months ago

Ernexa Therapeutics plans ERNA-101 investigational new drug submission for Q3

May 27, 2026, 8:11 AM EDT - 3 months ago

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development

May 20, 2026, 8:31 AM EDT - 3 months ago

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity

May 11, 2026, 9:15 AM EDT - 3 months ago

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101

2026-05-07T21:58:10.000Z - 3 months ago

Ernexa Therapeutics initiated with a Buy at Brookline

2026-05-07T16:17:11.000Z - 3 months ago

3 Penny Stocks to Watch Now, 5/7/26

AHMA PMAX

2026-05-07T04:27:19.000Z - 3 months ago

Ernexa Therapeutics announces new ERNA-101 preclinical data

May 6, 2026, 8:33 AM EDT - 3 months ago

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

2026-04-30T19:19:12.000Z - 3 months ago

Ernexa Therapeutics announces 1-for-25 reverse stock split

Apr 30, 2026, 9:00 AM EDT - 3 months ago

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Mar 31, 2026, 8:55 AM EDT - 5 months ago

Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

2026-03-16T10:56:34.000Z - 5 months ago

Ernexa Therapeutics files $50M mixed securities shelf

Feb 20, 2026, 9:05 AM EST - 6 months ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

2026-02-06T14:30:30.000Z - 6 months ago

Ernexa Therapeutics prices 21M shares at 50c in public offering

Feb 6, 2026, 9:25 AM EST - 6 months ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Feb 3, 2026, 8:45 AM EST - 7 months ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

2026-02-03T11:21:14.000Z - 7 months ago

Ernexa Therapeutics files to sell common stock, warrants, no amount given

2026-01-27T13:52:07.000Z - 7 months ago

Ernexa selected as company for JETRO Japan entry acceleration program

Jan 27, 2026, 8:45 AM EST - 7 months ago

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

2026-01-06T13:38:50.000Z - 8 months ago

Ernexa Therapeutics completes Pre-IND meeting with FDA

Jan 6, 2026, 8:15 AM EST - 8 months ago

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Dec 8, 2025, 8:30 AM EST - 9 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

Dec 3, 2025, 8:30 AM EST - 9 months ago

Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2025, 8:50 AM EST - 9 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D.

Nov 11, 2025, 7:00 AM EST - 10 months ago

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 10, 2025, 8:35 AM EST - 10 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 6, 2025, 9:15 AM EST - 10 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Oct 29, 2025, 8:33 AM EDT - 10 months ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 1, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Sep 29, 2025, 8:30 AM EDT - 11 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 17, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 10, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 1 year ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 1 year ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 1 year ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 2 years ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 2 years ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

2pumps1dump Aug. 18 at 7:28 PM

$ERNA

0 · Reply

JimmyOcarri Aug. 17 at 7:43 PM

$ARBB $STFS $XXII $ERNA $SLMT gemss

0 · Reply

Gdori Aug. 15 at 6:23 AM

$ERNA When will they announce the results?

0 · Reply

2pumps1dump Aug. 12 at 5:39 AM

$ERNA IND Submission

0 · Reply

Equilibrium_For_All Aug. 11 at 7:26 PM

$ERNA will someone just buy here.... Volume so low. Any small buys sends this up, imagine a bigger buy, it would fly!

0 · Reply

2pumps1dump Aug. 11 at 6:05 AM

$ERNA primed, oversold.

0 · Reply

Ernexatx Aug. 10 at 2:06 PM

0 · Reply

SuminskiStonks Aug. 7 at 1:35 PM

$ERNA Some good news and let’s take this back to 12-15

0 · Reply

KiserSose Aug. 7 at 2:40 AM

$ERNA Float is less than 700k

0 · Reply

KiserSose Aug. 7 at 2:35 AM

$ERNA all this stock needs is good news..10 bucks here we come

0 · Reply

Zephix Aug. 6 at 11:20 PM

$ERNA 9-10$

0 · Reply

Flowjob Aug. 5 at 2:18 PM

$ERNA FDA IND News due. CTB over 200%

0 · Reply

2pumps1dump Aug. 5 at 8:58 AM

$ERNA bags are packed

0 · Reply

KiserSose Aug. 4 at 8:21 PM

$ERNA Something seems up . It's up around 1.00 to 4.42

0 · Reply

Ernexatx Jul. 29 at 4:21 PM

$ERNA - Building breakthrough therapies through compelling science, independent validation and disciplined execution. ERNA-101 is on track for a Q3 IND submission and first-in-human study in Q4. Following compelling preclinical data, we believe 2026 has the potential to be a significant value creation year. https://www.ernexatx.com/

0 · Reply

Ernexatx Jul. 24 at 1:33 PM

$ERNA CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies https://bit.ly/44LT3JU

0 · Reply

Stock_Catcher Jul. 24 at 1:20 PM

$ERNA Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

0 · Reply

KiserSose Jul. 23 at 8:32 PM

$ERNA how low can you go. Doin' the Limbo rock drop

0 · Reply

CometaMan Jul. 23 at 7:26 PM

$ERNA Doing the Nasty thing 🤮as usual! Another -10, Let's see where this goes AH? lol🐻🤑

0 · Reply

WVU1 Jul. 23 at 11:51 AM

$ERNA One can hope it comes back up .

0 · Reply

Market Cap	1.43M
Revenue (ttm)	580,000.00
Net Income (ttm)	-44.54M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,679.31%
Debt to Equity Ratio	0.00

Volume	359,085
Avg Vol	12,707,749
Day's Range	N/A - N/A
Shares Out	5.41M
Stochastic %K	48%
Beta	4.47
Analysts	Hold
Price Target	N/A